Study of COVID-19 Vaccine Safety in Multiple Sclerosis Patient Cohort
46
1 comment
The lead author of this study, Farren B.S. Briggs, from the Department of Public Health Science, University of Miami Miller School of Medicine, and collaborators aimed to explore self-reported COVID-19 vaccine reactogenicity among persons with multiple sclerosis (PwMS), focusing on short-term reactions across multiple doses and vaccine sequences. The hypothesis examines whether reactogenicity profiles among PwMS differ by vaccine type, sequence, and clinical characteristics such as age and disease-modifying therapies (DMTs).
The Study
Quality journalism costs money to produce.
Free access provides up to 10 articles
Subscription options start at $5 per month
which is less than a Starbucks coffee!
Peter Gabriel, MD
"Publishing on TrialSite helped me secure a $20m research grant for my work."
Jona Savinda
"TrialSiteNews is my daily read for what is happening in the industry."
Lucas Van Der Hoven
"Objective, unbiased reporting on the latest news in medical research. I trust TrialSiteNews to give it to me straight."
Publish on TrialSite
TrialSiteNews
159 W Broadway, Suite 200
Salt Lake City, UT 84101
© 2025 - Trial Site News